Sumetrol Suspension 50 ML

Sumetrol Suspension 50 ML interacts with the following medicines:

• HIV medications such as Zidovudine: The concomitant use may increase the risk of haematological adverse effects such as anaemia or neutropenia.
• Immunosuppressants such as Cyclosporin: The concomitant use may cause reversible deterioration in renal function, especially in transplant patients.
• Antitubercular medications such as Rifampicin: The concomitant use may reduce trimethoprim levels by shortening its half-life, potentially decreasing effectiveness.
• Antimalarial medications such as Pyrimethamine: The concomitant use may increase the risk of megaloblastic anaemia, particularly at higher doses.
• Anticoagulants such as Warfarin: The concomitant use may enhance anticoagulant effects, increasing the risk of bleeding.
• Antiepileptic medications such as Phenytoin: The concomitant use may prolong the half-life of phenytoin, increasing the risk of toxicity.
• Cardiac glycosides such as Digoxin: The concomitant use may increase plasma digoxin levels, particularly in older patients.
• Antimetabolites such as Methotrexate: The concomitant use may increase methotrexate levels, leading to enhanced toxicity.
• Antiretroviral medications such as Lamivudine: The concomitant use may increase lamivudine exposure due to the trimethoprim component.
• Antihypertensives such as ACE inhibitors and potassium-sparing diuretics such as spironolactone: The concomitant use may increase the risk of hyperkalaemia.
• Antidiabetic medications such as sulphonylureas and repaglinide: The concomitant use may enhance hypoglycaemic effects, increasing the risk of low blood sugar.
• Folate supplements such as Folinic acid: The concomitant use may reduce the antibacterial effectiveness of Sumetrol Suspension 50 ML.

Sumetrol Suspension 50 ML interacts with the following conditions:

• Blood disorders: The use of Sumetrol Suspension 50 ML may further suppress bone marrow function, worsening conditions such as anaemia, agranulocytosis, or other blood dyscrasias.
• G6PD deficiency: The use of Sumetrol Suspension 50 ML may trigger haemolysis due to oxidative stress on red blood cells in patients with this enzyme deficiency.
• Porphyria: The use of Sumetrol Suspension 50 ML may precipitate or worsen porphyria symptoms by interfering with haem metabolism.
• Electrolyte imbalance: The use of Sumetrol Suspension 50 ML may increase the risk of hyperkalaemia and hyponatraemia, particularly in patients with pre-existing imbalances or renal impairment.
• Asthma or severe allergies: The use of Sumetrol Suspension 50 ML may increase the likelihood of hypersensitivity reactions, including severe allergic or respiratory responses.

The recommended dose of Sumetrol Suspension 50 ML is determined by your doctor based on age, body weight, infection severity, and clinical response. Follow the prescribed schedule strictly.

Overdose of Sumetrol Suspension 50 ML may cause nausea, vomiting, dizziness, confusion, or electrolyte imbalance. Immediate medical attention is required.

If a dose of Sumetrol Suspension 50 ML is missed, administer it as soon as remembered. If it is close to the next scheduled dose, skip the missed dose. Do not double the dose.